Bcl-xL as a poor prognostic biomarker and predictor of response to adjuvant chemotherapy specifically in BRAF -mutant stage II and III colon cancer
Published version of a preprint
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“We and others have showed the association of MCL1 and Bcl-xL expression with tumor progression and survival in solid tumors including CRC [30, 48–52].”
From MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma (2022) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marisa, L., de Reyniès, A., Duval, A., Selves, J., Gaub, M. P., Vescovo, L., Etienne-Grimaldi, M.-C., Schiappa, R., Guenot, D., Ayadi, M., et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001453 · Cited by 1,507
Maughan, T. S., Adams, R. A., Smith, C. G., Meade, A. M., Seymour, M. T., Wilson, R. H., Idziaszczyk, S., Harris, R., Fisher, D., Kenny, S. L., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60613-2 · Cited by 960
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · cited 12×
“The reason for the significant benefit from standard chemotherapy of Bcl-xL high BRAFMT CRC is unclear.”
BackgroundInfluentialThe Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551 · cited 1×
“Additionally, a further drug screeningbased study identified Bcl-xL as a critical regulator of MEK inhibitor resistance, which was synthetically lethal across a broad panel of BRAFMT cell line models [17].”
BackgroundIdentification of a Poor-Prognosis BRAF-Mutant–Like Population of Patients With Colon Cancer
Popovici, V., Budinska, E., Tejpar, S., Weinrich, S., Estrella, H., Hodgson, G., Van Cutsem, E., Xie, T., Bosman, F. T., Roth, A. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5814 · Cited by 236
Self-citationFaber, A. C., Coffee, E. M., Costa, C., Dastur, A., Ebi, H., Hata, A. N., Yeo, A. T., Edelman, E. J., Song, Y., Tam, A. T., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0315 · Cited by 124 · cited 1×
“[14, 15] A recent high-throughput drug screen aimed at uncovering therapeutic strategies in CRC, revealed the essentiality of MCL1, Bcl-2 and Bcl-xL in BRAFMTdriven disease [16].”
BackgroundMao, C., Wu, X.-Y., Yang, Z.-Y., Threapleton, D. E., Yuan, J.-Q., Yu, Y.-Y., & Tang, J.-L. (2015) · Scientific Reports · doi:10.1038/srep08065 · Cited by 107 · cited 1×
“Signaling through the Epidermal Growth Factor Receptor (EGFR) pathway is a common event in cancer development [1], with activating mutations in KRAS, NRAS and BRAF occurring in approximately 50% of colorectal cancer (CRC) patients [2].”
BackgroundBCL-2 system analysis identifies high-risk colorectal cancer patients
Lindner, A. U., Salvucci, M., Morgan, C., Monsefi, N., Resler, A. J., Cremona, M., Curry, S., Toomey, S., O'Byrne, R., Bacon, O., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-312287 · Cited by 50 · cited 12×
“The reason for the significant benefit from standard chemotherapy of Bcl-xL high BRAFMT CRC is unclear.”
InfluentialSelf-citation
Research works printed but not linked: 16
- Yatabe, 2010, Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer, FEBS J, 277, 301, 10.1111/j.1742-4658.2009.07448.x · DOI · Paper page
- Lebbe, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782 · DOI · Paper page
- Bernards, 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, Nature, 483, 100, 10.1038/nature10868 · DOI · Paper page
- Kalisky, 2016, CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer, N Engl J Med, 374, 211, 10.1056/NEJMoa1506597 · DOI · Paper page
- Kang, 2015, Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients, World J Gastroenterol, 21, 1457, 10.3748/wjg.v21.i5.1457 · DOI
- Lugli, 2010, Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis, Int J Cancer, 127, 367, 10.1002/ijc.25042 · DOI · Paper page
- Wei, 2011, Prognostic significance of Bcl-xL gene expression in human colorectal cancer, Acta Histochem, 113, 810, 10.1016/j.acthis.2011.01.002 · DOI
- Bussey, 1958, The spread of rectal cancer and its effect on prognosis, Br J Cancer, 12, 309, 10.1038/bjc.1958.37 · DOI · Paper page
- Letai, 2006, Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members, Cancer Cell, 9, 351, 10.1016/j.ccr.2006.03.027 · DOI · Paper page
- Corbett, 2017, Developmental Regulation of Mitochondrial Apoptosis by c-Myc Governs Age- and Tissue-Specific Sensitivity to Cancer Therapeutics, Cancer Cell, 31, 142, 10.1016/j.ccell.2016.11.011 · DOI · Paper page
- Slaby, 2016, Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer, Oncotarget, 7, 622, 10.18632/oncotarget.5807 · DOI · Paper page
- Pantel, 2015, Disseminated Tumor Cells Persist in the Bone Marrow of Breast Cancer Patients through Sustained Activation of the Unfolded Protein Response, Cancer Res, 75, 5367, 10.1158/0008-5472.CAN-14-3728 · DOI
- Brandt, 2010, Discovery of a novel unfolded protein response phenotype of cancer stem/progenitor cells from the bone marrow of breast cancer patients, J Proteome Res, 9, 3158, 10.1021/pr100039d · DOI
- Yang, 2013, Uncovering a key to the process of metastasis in human cancers: a review of critical regulators of anoikis, J Cancer Res Clin Oncol, 139, 1795, 10.1007/s00432-013-1482-5 · DOI
- Simon, 2015, The consensus molecular subtypes of colorectal cancer, Nat Med, 21, 1350, 10.1038/nm.3967 · DOI · Paper page
- Hamilton, 2017, QuPath: Open source software for digital pathology image analysis, Sci Rep, 7, 16878, 10.1038/s41598-017-17204-5 · DOI · Paper page
Cited by
Co-targeting of BAX and BCL-XL proteins broadly overcomes resistance to apoptosis in cancer
Lopez, A., Reyna, D. E., Gitego, N., Kopp, F., Zhou, H., Miranda-Roman, M. A., Nordstrøm, L. U., Narayanagari, S.-R., Chi, P., Vilar, E., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28741-7 · Cited by 196
MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma
Fu, D., Pfannenstiel, L., Demelash, A., Phoon, Y. P., Mayell, C., Cabrera, C., Liu, C., Zhao, J., Dermawan, J., Patil, D., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-021-04334-y · Cited by 29
Metadata
- Authors
- Dunne, P. D., Coleman, H. G., Bankhead, P., Alderdice, M., Gray, R. T., McQuaid, S., Bingham, V., Loughrey, M. B., James, J. A., McCorry, A. M. B., Gilmore, A., Holohan, C., Klingbiel, D., Tejpar, S., Johnston, P. G., McArt, D. G., Nicolantonio, F. D., Longley, D. B., & Lawler, M.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2018-02-13
- Volume
- 9
- Issue
- 17
- Pages
- 13834-13847
- ISSN
- 1949-2553
- Cited by
- 10
- References
- 8
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.